Association of Genomic Alterations with the Presence of Serum Monoclonal Proteins in Chronic Lymphocytic Leukemia.

Autor:	Piñeyroa JA; Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Facultat de Medicina i Ciènces de la Salut, Universitat de Barcelona, 08036 Barcelona, Spain., López-Oreja I; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Nadeu F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Martínez-Farran A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain., Aróstegui JI; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Immunology, Hospital Clínic, 08036 Barcelona, Spain., López-Guerra M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Correa JG; Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain., Fabregat A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Biochemistry and Molecular Genetics, Hospital Clínic, 08036 Barcelona, Spain., Villamor N; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Monge-Escatín I; Pharmacy Unit, Hospital Clínic de Barcelona, 08036 Barcelona, Spain., Albiol N; Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain., Costa D; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Aymerich M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Beà S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Facultat de Medicina i Ciènces de la Salut, Universitat de Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Campo E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Facultat de Medicina i Ciènces de la Salut, Universitat de Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Delgado J; Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Facultat de Medicina i Ciènces de la Salut, Universitat de Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Colomer D; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Facultat de Medicina i Ciènces de la Salut, Universitat de Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Hematopathology Unit, Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain., Mozas P; Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Cells [Cells] 2024 Nov 07; Vol. 13 (22). Date of Electronic Publication: 2024 Nov 07.
DOI:	10.3390/cells13221839
Abstrakt:	The presence of a monoclonal protein detected by serum immunofixation electrophoresis (sIFE) has been reported as an adverse prognostic factor in chronic lymphocytic leukemia (CLL). However, the genetic underpinning of this finding has not been studied. We retrospectively studied 97 CLL patients with simultaneous information on sIFE and genetic alterations detected by next-generation sequencing. sIFE was positive in 49 patients. The most common isotypes were IgG κ (27%) and bi/triclonal (25%). A +sIFE was associated with a higher number of mutated genes [median 2 (range 0-3) vs. 0 (range 0-2), p = 0.006], and a higher frequency of unmutated IGHV status (60 vs. 29%, p = 0.004). An IgM monoclonal protein was associated with TP53 mutations (36% in IgM +sIFE vs. 12% in non-IgM +sIFE or -sIFE, p = 0.04), and bi/triclonal proteins with NOTCH1 mutations (33% in bi/triclonal vs. 9% in monoclonal +sIFE or -sIFE, p = 0.04). These data suggest an association between a +sIFE and a higher mutational burden, and some monoclonal isotypes with specific mutations.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu